- Home
- TWLO vs GMAB Comparison
TWLO vs GMAB Comparison
Compare TWLO & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TWLO
- GMAB
- Stock Information
- Founded
- TWLO 2008
- GMAB 1999
- Country
- TWLO United States
- GMAB Denmark
- Employees
- TWLO N/A
- GMAB N/A
- Industry
- TWLO Computer Software: Prepackaged Software
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- TWLO Technology
- GMAB Health Care
- Exchange
- TWLO Nasdaq
- GMAB Nasdaq
- Market Cap
- TWLO 16.7B
- GMAB 15.4B
- IPO Year
- TWLO 2016
- GMAB N/A
- Fundamental
- Price
- TWLO $103.60
- GMAB $28.08
- Analyst Decision
- TWLO Buy
- GMAB Buy
- Analyst Count
- TWLO 26
- GMAB 6
- Target Price
- TWLO $132.81
- GMAB $37.60
- AVG Volume (30 Days)
- TWLO 2.6M
- GMAB 1.5M
- Earning Date
- TWLO 10-29-2025
- GMAB 11-05-2025
- Dividend Yield
- TWLO N/A
- GMAB N/A
- EPS Growth
- TWLO N/A
- GMAB 77.72
- EPS
- TWLO 0.13
- GMAB 21.62
- Revenue
- TWLO $4,729,372,000.00
- GMAB $3,646,881,232.00
- Revenue This Year
- TWLO $13.05
- GMAB $24.52
- Revenue Next Year
- TWLO $8.15
- GMAB $15.53
- P/E Ratio
- TWLO $820.83
- GMAB $1.30
- Revenue Growth
- TWLO 11.56
- GMAB 32.97
- 52 Week Low
- TWLO $59.86
- GMAB $17.24
- 52 Week High
- TWLO $151.95
- GMAB $28.75
- Technical
- Relative Strength Index (RSI)
- TWLO 44.59
- GMAB 70.89
- Support Level
- TWLO $100.70
- GMAB $27.81
- Resistance Level
- TWLO $104.84
- GMAB $28.75
- Average True Range (ATR)
- TWLO 3.22
- GMAB 0.39
- MACD
- TWLO 0.33
- GMAB 0.05
- Stochastic Oscillator
- TWLO 27.49
- GMAB 83.35
About TWLO Twilio Inc.
Twilio is a cloud-based communications platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.